Mark Trautwein is a Senior Scientific Director in Therapeutic Antibodies at Bayer, where they currently head the Immunoprofiling Group in Biologics Research. Since 2017, they have held various leadership roles, including Senior Scientist and Project Leader, where they have focused on antibody design and optimization, project leadership in targeted cancer therapies, and establishing innovative cell-based assays. Mark also plays a crucial role in managing collaborations and advancing research initiatives in advanced therapies at Bayer.
This person is not in the org chart
This person is not in any teams
This person is not in any offices